Presbyopia eye drops
Anti-crosslinking drug may restore natural accommodation


Howard Larkin
Published: Tuesday, July 11, 2017

EV06 targets disulfide bonds that form among proteins in the crystalline lens in response to oxidative challenge and UV light that both stiffen and cloud the lensEventually, EV06 or a similar preparation might also help slow or even reverse nuclear cataract formation, which is thought to result from the same chemical process that causes presbyopia, added Dr Lindstrom, who is founder of Minnesota Eye Consultants, Bloomington, Minnesota, USA, and a board member and equity owner of Encore Vision. EV06 targets disulfide bonds that form among proteins in the crystalline lens in response to oxidative challenge and UV light that both stiffen and cloud the lens. The choline preparation helps the compound penetrate the cornea. Inside the eye, it reduces to lipoic acid and dihydrolipoic acid, which in turn dissolve the disulfide bonds. “We’re basically un-crosslinking the natural lens,” Dr Lindstrom said. In the clinical trial, involving 75 patients, EV06 worked faster than expected, and the effect increased progressively throughout the trial, Dr Lindstrom said. Mean logMAR distance corrected near visual acuity in the treatment group improved from 0.397 at baseline to 0.206 at day 91, compared with 0.408 at baseline to 0.313 at day 91 in the control group. At day 91, 84% reached 20/40 or better from a baseline of 30% in the treatment group, compared with 48% from 28% among controls. Overall, 84% of treated patient gained at least one line of near vision, 53% two or more lines and 22% three lines, and 12% four lines at 90 days, with no loss of corrected distance vision. While a few patients reported minor irritation taking EV06 twice daily, comfort scores were similar in the treatment and placebo groups. No significant adverse events were observed and no patients dropped out of the trial. A post-treatment study found the treated group continued to show better near vision than controls out to 301 days, though the effect declined slightly over time, Dr Lindstrom added. Richard L Lindstrom: rllindstrom@ mneye.com
Tags: presbyopia
Latest Articles
Committing to a More Equitable Ophthalmology
Charity Committee enhances ESCRS’s reputation as a socially responsible society.
Virtual Community Unites Ukrainian Eye Specialists
Microlearning platform proves vital to saving eyes and lives in areas of conflict.
ESCRS Survey Shifts Industry Dial
Annual survey reveals trends and issues regarding the digital OR.
Always Measure the Epithelium!
Epithelium thickness mapping key to better refractive outcomes.
Advancing Vision Research
National Eye Institute initiatives encourage AI-based innovations and data interoperability.
Best Candidates for Phakic EDOF IOLs?
Patient profile suggests limits for phakic EDOF approach.
Knowing Iris Repair: Iris Repair with Prosthetic Devices
New devices on the market expand available options when iris tissue is insufficient.
Targeting the Kallikrein-Kinin System to Treat DME
Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.
Faricimab VOYAGER Study
Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.